Sanofi, a France-based multinational pharmaceutical company, is investing EUR80m in equity in BioNTech, which is claimed to be Europe's largest privately-held biopharmaceutical firm focused on the development of individualised therapies for cancer and the prevention of infectious diseases, it was reported yesterday.
According to the contract, BioNTech is eligible to receive USD60m in upfront and near-term milestone payments. The firm is also eligible to receive more than USD300m in development, regulatory and commercial milestones and other payments per product.
The company has the option to co-develop and co-commercialiSe two of the five mRNA therapeutics products with Sanofi in the European Union and the United States.
INOVIO announces inducement grant to new employee
Hologic receives FDA clearance and CE mark for new gastrointestinal bacterial assays
LakeShore Biopharma receives Nasdaq delisting determination letter
CorMedix to acquire Melinta Therapeutics in USD300m deal to expand infectious disease portfolio
INOVIO to release Q2 2025 financial results on 12 August
Bavarian Nordic chikungunya vaccine enters Health Canada review process
Ondine Biomedical completes world-first ICU study with Steriwave nasal therapy
Centivax raises USD45m to commercialise universal flu vaccine
SCG Cell's SCG101V therapy Investigational New Drug Application receives Chinese regulatory approval
INOVIO prices USD25m public offering
Blacksmith Medicines granted US patent for antibacterial compounds targeting LpxC
Seegene launches STAgora infectious disease analytics platform
hVIVO supports Cidara Therapeutics' positive Phase 2b influenza study results